IL198690A0 - Compounds for inhibiting mitotic progression - Google Patents

Compounds for inhibiting mitotic progression

Info

Publication number
IL198690A0
IL198690A0 IL198690A IL19869009A IL198690A0 IL 198690 A0 IL198690 A0 IL 198690A0 IL 198690 A IL198690 A IL 198690A IL 19869009 A IL19869009 A IL 19869009A IL 198690 A0 IL198690 A0 IL 198690A0
Authority
IL
Israel
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
progression
Prior art date
Application number
IL198690A
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL198690(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IL198690A0 publication Critical patent/IL198690A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL198690A 2006-11-16 2009-05-11 Compounds for inhibiting mitotic progression IL198690A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
IL198690A0 true IL198690A0 (en) 2010-02-17

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL198690A IL198690A0 (en) 2006-11-16 2009-05-11 Compounds for inhibiting mitotic progression

Country Status (34)

Country Link
US (7) US8026246B2 (OSRAM)
EP (4) EP2086981B1 (OSRAM)
JP (3) JP5102839B2 (OSRAM)
KR (2) KR101342014B1 (OSRAM)
CN (2) CN101547924B (OSRAM)
AR (1) AR064246A1 (OSRAM)
AT (1) ATE556076T1 (OSRAM)
AU (1) AU2007322046B2 (OSRAM)
BR (1) BRPI0718803B8 (OSRAM)
CA (1) CA2669680C (OSRAM)
CL (1) CL2007003244A1 (OSRAM)
CR (3) CR10782A (OSRAM)
CY (1) CY1112828T1 (OSRAM)
DK (2) DK2497772T3 (OSRAM)
EA (1) EA015779B1 (OSRAM)
ES (3) ES2537451T3 (OSRAM)
GE (1) GEP20125459B (OSRAM)
HR (2) HRP20120490T1 (OSRAM)
IL (1) IL198690A0 (OSRAM)
MA (1) MA30988B1 (OSRAM)
MX (3) MX2009004670A (OSRAM)
MY (1) MY153243A (OSRAM)
NO (1) NO343338B1 (OSRAM)
NZ (3) NZ611898A (OSRAM)
PH (1) PH12012502057B1 (OSRAM)
PL (2) PL2497772T3 (OSRAM)
PT (2) PT2497772E (OSRAM)
RS (2) RS53788B1 (OSRAM)
SG (2) SG176443A1 (OSRAM)
SI (2) SI2086981T1 (OSRAM)
TW (1) TWI401255B (OSRAM)
UA (1) UA94129C2 (OSRAM)
WO (1) WO2008063525A1 (OSRAM)
ZA (1) ZA200903279B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193750B (zh) 2004-05-14 2018-04-27 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2010065134A1 (en) * 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011161031A1 (en) * 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
US11340215B2 (en) 2016-02-26 2022-05-24 Japanese Foundation For Cancer Research Screening method of anticancer agent focused on function of HP1 and evaluation system
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
IL317823A (en) 2022-06-30 2025-02-01 Lilly Co Eli KRAS G12C inhibitor for cancer treatment
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU723860B2 (en) 1996-03-08 2000-09-07 Astrazeneca Ab Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
TW510902B (en) * 1997-09-29 2002-11-21 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU1651201A (en) 1999-12-06 2001-06-18 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
CN102250071A (zh) * 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
AU2002328999B8 (en) 2001-08-09 2008-06-05 Actelion Pharmaceuticals Ltd. Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN104193750B (zh) * 2004-05-14 2018-04-27 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
EP2086981B1 (en) 2012-05-02
ES2537451T3 (es) 2015-06-08
US20240400567A1 (en) 2024-12-05
US9765076B2 (en) 2017-09-19
CA2669680C (en) 2012-04-10
EP2944639A1 (en) 2015-11-18
JP5452811B2 (ja) 2014-03-26
US20110312943A1 (en) 2011-12-22
EP2086981A1 (en) 2009-08-12
PT2497772E (pt) 2015-02-05
RS52313B (sr) 2012-12-31
JP5102839B2 (ja) 2012-12-19
TWI401255B (zh) 2013-07-11
CR10782A (es) 2009-06-24
KR101110458B1 (ko) 2012-03-13
PL2497772T3 (pl) 2015-05-29
KR20110113210A (ko) 2011-10-14
JP2014055166A (ja) 2014-03-27
US9988384B2 (en) 2018-06-05
EA015779B1 (ru) 2011-12-30
ATE556076T1 (de) 2012-05-15
BRPI0718803B1 (pt) 2020-11-17
NZ597252A (en) 2013-06-28
SG10201503350TA (en) 2015-06-29
KR20090091173A (ko) 2009-08-26
CN103483343A (zh) 2014-01-01
ES2528793T3 (es) 2015-02-12
AR064246A1 (es) 2009-03-25
SG176443A1 (en) 2011-12-29
CR20140544A (es) 2015-01-12
NZ611898A (en) 2015-01-30
SI2497772T1 (sl) 2015-03-31
CN101547924B (zh) 2013-09-25
BRPI0718803A2 (pt) 2013-12-03
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
EP2497773A1 (en) 2012-09-12
CN101547924A (zh) 2009-09-30
GEP20125459B (en) 2012-03-26
RS53788B1 (sr) 2015-06-30
HRP20120490T1 (hr) 2012-07-31
NZ577042A (en) 2012-03-30
US11958855B2 (en) 2024-04-16
US8026246B2 (en) 2011-09-27
US20110312942A1 (en) 2011-12-22
MY153243A (en) 2015-01-29
MA30988B1 (fr) 2009-12-01
AU2007322046A1 (en) 2008-05-29
DK2086981T3 (da) 2012-08-06
KR101342014B1 (ko) 2013-12-19
EP2944639B1 (en) 2017-01-04
US20190031662A1 (en) 2019-01-31
CN103483343B (zh) 2016-06-01
US10836766B2 (en) 2020-11-17
UA94129C2 (ru) 2011-04-11
CL2007003244A1 (es) 2008-04-04
US20080167292A1 (en) 2008-07-10
CY1112828T1 (el) 2016-02-10
CR20140154A (es) 2014-07-23
EP2497772B1 (en) 2014-10-29
MX343391B (es) 2016-11-04
ES2384123T3 (es) 2012-06-29
NO20091864L (no) 2009-06-15
AU2007322046B2 (en) 2012-04-05
JP2012006965A (ja) 2012-01-12
HK1217699A1 (en) 2017-01-20
EP2497772A1 (en) 2012-09-12
EP2497773B1 (en) 2015-02-25
US20210214361A1 (en) 2021-07-15
NO343338B1 (no) 2019-02-04
TW200829589A (en) 2008-07-16
JP2010510215A (ja) 2010-04-02
EA200970486A1 (ru) 2009-10-30
DK2497772T3 (en) 2015-01-19
PL2086981T3 (pl) 2012-09-28
PH12012502057A1 (en) 2015-09-14
HRP20150047T1 (en) 2015-03-13
ZA200903279B (en) 2010-07-28
MX348568B (es) 2017-06-20
BRPI0718803B8 (pt) 2021-05-25
WO2008063525A1 (en) 2008-05-29
CA2669680A1 (en) 2008-05-29
US20150166545A1 (en) 2015-06-18
HK1175777A1 (en) 2013-07-12
PH12012502057B1 (en) 2018-10-24
HK1134672A1 (en) 2010-05-07
SI2086981T1 (sl) 2012-12-31
HK1175778A1 (en) 2013-07-12

Similar Documents

Publication Publication Date Title
IL198690A0 (en) Compounds for inhibiting mitotic progression
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
EP2082022A4 (en) COMPOUNDS
GB0605785D0 (en) Compounds
GB0605784D0 (en) Compounds
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0602042D0 (en) Compounds
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP1973905A4 (en) COMPOUNDS
GB0600427D0 (en) Compounds
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
HK1131386A (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
GB0604375D0 (en) Compounds
GB0602856D0 (en) Compounds
GB0602454D0 (en) Compounds
GB0602455D0 (en) Compounds
GB0602134D0 (en) Compounds
GB0602558D0 (en) Compounds
GB0602559D0 (en) Compounds
GB0602040D0 (en) Compounds
GB0601505D0 (en) Compounds
GB0600929D0 (en) Compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed